Stereotactic Radiosurgery Dose Escalation for Brain Metastases

This study is testing a treatment called Stereotactic Radiosurgery (SRS) for people with 1 to 5 brain metastases (cancers that have spread to the brain). The main goal is to find the highest safe dose of SRS for these brain tumors, especially for patients who haven't had radiation to their brain before. You would be assigned to one of four groups based on the size of your brain lesions. One lesion will receive an experimental dose, while others will get standard SRS doses. The study will look at any side effects you might experience. The study is currently unclear on its recruitment status.

Study design: This is a Phase I dose escalation and expansion study, meaning it aims to find the safest and most effective dose of a treatment. It plans to enroll 86 participants.
What's involved: You would receive Stereotactic Radiosurgery treatment. The study will evaluate your progress and any side effects for up to 16 weeks.
Compensation: Not stated in the trial record.
Follow-up: Your adverse events will be monitored for up to 16 weeks after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Stereotactic Radiosurgery Dose Escalation for Brain Metastases

Recruiting

PHASE1Ages 18+InterventionalTreatment

University of Utah

~86 participants

Updated 2026-07-02 on ClinicalTrials.gov

What's tested:Stereotactic Radiosurgery

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Maximum Tolerated Dose of stereotactic radiosurgery

Measured over Maximum Tolerated Dose of stereotactic radiosurgery will be evaluated throughout the treatment period which is expected to last 12-16 weeks per patient

+1 more outcome measured

Conditions

Brain Metastases

Where it's being run

1 sites across 1 states

Utah1

Study leadership

Lindsay Burt, MD · PRINCIPAL_INVESTIGATOR · Huntsman Cancer Institute

Who to contact

David Ostler

[email protected]

801-585-0550

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Clinically confirmed brain metastases by CT or MRI criteria. If there is evidence of extra-cranial metastatic disease, it is preferable that the lesions be pathologically confirmed (see section 4.2.5 for excluded histologies) and reviewed by a University of Utah or Huntsman Cancer Hospital pathologist if the initial review was done at an outside facility.

Prior brain surgery is allowed, although a lesion situated in the operative bed would not be selected to receive an experimental dose of SRS treatment. SRS should be delivered 4-6 weeks post-surgery if the patient had a craniotomy for resection of a lesion. Enrollment of a patient with the goal of performing SRS outside of the 4-6 post-craniotomy window is at the PI's discretion.

Patients must have 1-5 untreated brain metastases total.

For patients planning to enroll in Cohort 1a (including expansion) or Cohort 1b: Tumor volume ≤ 4.1888 cm3 by CT or MRI measurement at the time of consultation/screening for the metastatic lesion on trial. Patients who have at least one additional lesion that is larger than the lesions eligible for the expansion cohort, but who are unable to find another open cohort, will have the eligible lesion(s) treated in the expansion cohort, and the remaining lesion(s) treated at the standard dose.

For patients enrolling in the expansion Cohort 1a: Up to five brain metastases with tumor volume ≤ 0.5237 cm3 by CT or MRI measurement at the time of consultation/screening will be treated on trial with the MTD. Brain metastases with volume \> 0.5237 cm3 will be treated by standard of care SRS dosing.

For patients enrolling in Cohort 1b: Tumor volume of \> 0.5237 cm3 and ≤ 4.1888 cm3 by CT or MRI measurement at the time of consultation/screening for the metastatic lesion on trial. All other brain metastases will be treated by standard of care SRS dosing.

As of Protocol Version 9, Cohorts 2 and 3 are permanently closed to accrual. For patients planning to enroll in Cohort 2 or 3: Equivalent tumor diameter ≤ 40 mm by CT or MRI measurement at the time of consultation/screening for the metastatic lesion on trial. Equivalent tumor diameter \</=40 mm by CT or MRI measurement for all lesions treated by standard of care SRS dosing.

All metastatic lesions must be separated by a minimum of 3 cm as measured from the peripheral edges of the lesions that are in closest proximity to one another. If multiple lesions are present and are not all ≥ 3 cm away from each other, the patient will be deemed ineligible.

Prior systemic therapy is allowed, although appropriate washout is required for patients who have been on BRAF inhibitors (at least 7 days).

For subjects currently on active systemic cancer therapy, the treating medical oncologist should be consulted to ensure proper washout (if appropriate) periods prior to SRS.

Patients must be at least 18 years of age.

Karnofsky Performance Status (KPS) ≥ 60.

Able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines.

Women of child-bearing potential must have a negative pregnancy test within 10 days of study enrollment and must agree to use an acceptable method of birth control while receiving radiation and for 3 months after radiation. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for \>1 year.

Men who are able to father a child must agree to use an acceptable method of birth control while receiving radiation, and for 3 months after radiation.

Exclusion

Prior whole brain irradiation.

Brain lesions with an equivalent diameter of \> 40 mm in size on MRI imaging at the time of consultation/screening for protocol eligibility.

Lesions located in anatomic regions that are not amendable to SRS (e.g., optic nerve)

Brain lesions located in the brain stem.

Radiographic or cytologic evidence of leptomeningeal disease

Primary lesion with radiosensitive histology that includes the following: small cell carcinoma, germ cell tumors, lymphoma, leukemia, or multiple myeloma

Women of child-bearing potential who are pregnant or breast feeding

Patients with multiple lesions, which by size criteria would be enrolled in a cohort that is full at the time of enrollment and the 12-16 weeks DLT period has not yet been reached.

What this trial measures

Maximum Tolerated Dose of stereotactic radiosurgeryMaximum Tolerated Dose of stereotactic radiosurgery will be evaluated throughout the treatment period which is expected to last 12-16 weeks per patient
To determine the maximum tolerated dose (MTD) of stereotactic radiosurgery (SRS) treatment for patients in the Escalation Cohort (with 1 to 5 brain metastases, who have not received prior whole brain radiotherapy) and patients in the Expansion Cohort (with up to 5 metastases per patient). Maximum Tolerated Dose of stereotactic radiosurgery will be evaluated throughout the treatment period which is expected to last 12-16 weeks per patient Patients will be evaluated for any grade 3 or greater toxicities attributed to the lesion treated with the escalated dose.
Frequency of Adverse Events (AEs)up to 16 weeks
up to 16 weeks

Trialytics